Investors Purchase High Volume of Call Options on Precigen (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) was the target of some unusual options trading on Thursday. Traders acquired 11,169 call options on the company. This represents an increase of 1,645% compared to the typical volume of 640 call options.

Analysts Set New Price Targets

PGEN has been the subject of a number of recent analyst reports. JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of Precigen in a report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Precigen in a report on Thursday. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, Precigen currently has a consensus rating of “Hold” and a consensus target price of $7.00.

Hedge Funds Weigh In On Precigen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. LexAurum Advisors LLC boosted its position in shares of Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 417,055 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Precigen by 27.9% during the 4th quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 12,578 shares in the last quarter. Synovus Financial Corp lifted its position in Precigen by 100.0% in the 3rd quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 49,065 shares in the last quarter. Barclays PLC lifted its position in Precigen by 190.4% in the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 124,141 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after acquiring an additional 149,829 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Price Performance

Shares of PGEN stock traded up $0.19 on Thursday, reaching $1.32. 2,784,702 shares of the company were exchanged, compared to its average volume of 2,168,293. The company has a market cap of $385.12 million, a price-to-earnings ratio of -2.39 and a beta of 1.65. The company has a 50-day moving average of $0.92 and a 200-day moving average of $1.06. Precigen has a one year low of $0.65 and a one year high of $1.93.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.